Literature DB >> 11959607

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.

Constance Delaugerre1, Anne-Geneviève Marcelin, Vincent Thibault, Gilles Peytavin, Tony Bombled, Marie-Valérie Bochet, Christine Katlama, Yves Benhamou, Vincent Calvez.   

Abstract

Adefovir dipivoxil (ADV) at a suboptimal concentration for human immunodeficiency virus type 1 (HIV-1) (10 mg once daily) can be used to treat hepatitis B virus (HBV) infection in HIV-1-HBV-coinfected patients and does not, even in the case of uncontrolled HIV-1 replication, select for either ADV mutations at codons 65 and 70 or any other particular HIV-1 reverse transcriptase resistance profile.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11959607      PMCID： PMC127167          DOI： 10.1128/AAC.46.5.1586-1588.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Adefovir for the treatment of HIV infection: if not now, when?

Authors:  J W Mellors
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

2.  Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

Authors:  J Kahn; S Lagakos; M Wulfsohn; D Cherng; M Miller; J Cherrington; D Hardy; G Beall; R Cooper; R Murphy; N Basgoz; E Ng; S Deeks; D Winslow; J J Toole; D Coakley
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

3.  Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.

Authors:  J M Cherrington; A S Mulato; M D Fuller; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

Authors:  Y Benhamou; M Bochet; V Thibault; V Calvez; M H Fievet; P Vig; C S Gibbs; C Brosgart; J Fry; H Namini; C Katlama; T Poynard
Journal:  Lancet       Date:  2001-09-01       Impact factor: 79.321

5.  Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.

Authors:  C A Boucher; W Keulen; T van Bommel; M Nijhuis; D de Jong; M D de Jong; P Schipper; N K Back
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 6.  Hepatitis B virus infection: resistance to antiviral agents.

Authors:  D Mutimer
Journal:  J Clin Virol       Date:  2001-06       Impact factor: 3.168

7.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

8.  Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Authors:  R Perrillo; E Schiff; E Yoshida; A Statler; K Hirsch; T Wright; K Gutfreund; P Lamy; A Murray
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

9.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.

Authors:  X Xiong; C Flores; H Yang; J J Toole; C S Gibbs
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

10.  K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.

Authors:  Z Gu; H Salomon; J M Cherrington; A S Mulato; M S Chen; R Yarchoan; A Foli; K M Sogocio; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191
View more
  8 in total

Review 1.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

2.  Update on Hepatitis B and C Coinfection in HIV.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 3.  Managing hepatitis B coinfection in HIV-infected patients.

Authors:  Marion G Peters
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

4.  Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Paul J Cote; Brent E Korba; Scott D Butler; Andrea L George; Ilia A Tochkov; William E Delaney; Shelly Xiong; John L Gerin; Bud C Tennant
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Future directions in the treatment of HIV-HBV coinfection.

Authors:  David M Iser; Sharon R Lewin
Journal:  HIV Ther       Date:  2009-07-01

Review 6.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 7.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

8.  Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.

Authors:  Karine Lacombe; Joël Gozlan; Anders Boyd; Pierre-Yves Boelle; Philippe Bonnard; Jean-Michel Molina; Patrick Miailhes; Caroline Lascoux-Combe; Lawrence Serfaty; Fabien Zoulim; Pierre-Marie Girard
Journal:  Antivir Ther       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.